<DOC>
	<DOCNO>NCT01406717</DOCNO>
	<brief_summary>SPIL1033 resemble gut hormone , increase insulin secretion , thus help reduce blood glucose level . The purpose study establish safety efficacy SPIL1033</brief_summary>
	<brief_title>Safety Efficacy SPIL1033 Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>SPIL1033 subcutaneous injection indicate adjunctive therapy improve glycemic control patient type 2 diabetes mellitus . In study , efficacy safety SPIL1033 evaluate . Subjects receive SPIL1033 placebo , 5 mcg twice daily first 4 week 10 mcg twice daily remain 20 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female subject 20 year age older . Established clinical diagnosis type 2 diabetes mellitus treat diet exercise antidiabetic agent monotherapy combination therapy . Weight stable : weight vary 10 % screen visit weight , within 6 month prior screen visit . Women child bear potential practicing acceptable method birth control judge investigator ( ) ; negative urine pregnancy test . Willing participate give write informed consent . Previous exposure exenatide ( antiexenatide antibody screen ) GLP1 analogue . Used drug weight loss ( example , orlistat , sibutramine , phenylpropanolamine , rimonabant , similar overthecounter medication ) within 3 month screen . Received treatment within last 30 day drug receive regulatory approval indication time trial entry . Severe renal impairment ( creatinine clearance &lt; 30 ml/min ) end stage renal disease .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>SPIL1033</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
</DOC>